Cancer Therapy Effects on the Heart

Description

Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.

Conditions

Cardiotoxicity, Pediatric Cancer, Heart Failure

Talk to us

Study Overview

On this page

Study Details

Study overview

Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.

Cancer Therapy Effects on the Heart: Identification of Early Markers of Cardiac Disease Progression After Cardiotoxic Childhood Cancer Therapy Using Cardiac Magnetic Resonance Imaging

Cancer Therapy Effects on the Heart

Condition
Cardiotoxicity
Intervention / Treatment

-

Contacts and Locations

San Diego

Rady Children's Hospital, San Diego, California, United States, 92123

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * English and Spanish speaking male and female subjects, ages 13-39 years old
  • * Diagnosis of cancer at age \<22 years
  • * Previously treated with anthracyline therapy for cancer, with diagnosis at least two years prior.
  • * Patients who have a contraindication to cardiac MRI, including the presence of non-MRI compatible metallic implants.
  • * Medical, psychiatric, and/or social disorder that would prevent successful completion of planned study testing or would preclude the subject from undergoing the cardiac MRI without anesthesia.
  • * Patients with a history of congenital heart disease (more significant than a history of patent foramen ovale or patent ductus arteriosus).
  • * Patients with orthodontic braces or metallic implants in the thorax or abdomen/lumbar spine, even if MRI-compatible, will be excluded as these may cause artifacts and limit image quality.
  • * Pregnancy.

Ages Eligible for Study

13 Years to 39 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Hari Narayan,

Hari Narayan, MD, PRINCIPAL_INVESTIGATOR, University of California San Diego, Rady Children's Hospital

Study Record Dates

2029-09-30